GlycoMimetics makes good with $340m sickle cell drug deal with Pfizer

For a 22-employee biotech that just snagged a major deal with the world's largest drug maker, Gaithersburg, Maryland-based GlycoMimetics has much to be confident about, CEO Rachel King said, beaming about the new $340 million agreement her firm signed with Pfizer.